<DOC>
	<DOCNO>NCT00003748</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient esophageal stomach cancer .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Esophageal Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity irinotecan patient adenocarcinoma esophagus gastric cardia . II . Evaluate toxicity drug patient population . OUTLINE : This multicenter study . Patients receive irinotecan intravenous ( IV ) 90 minute week 4 week follow 2 week rest period . Treatment continue absence unacceptable toxicity disease progression . Patients follow every 3 month death . PROJECTED ACCRUAL : A total 18-32 patient accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients must &gt; 18 year age Patients must performance status 02 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Patients must predict life expectancy least 12 week Patients must pretreatment granulocyte count &gt; 1500/mm3 , hemoglobin level &gt; 9.0 gm/dL platelet count &gt; 100000/mm3 Patients must adequate renal function document serum creatinine &lt; 2.0 mg/dL Patients must adequate hepatic function document serum bilirubin &lt; 1.5 mg/dL , regardless whether patient liver involvement secondary tumor . Aspartate transaminase must &lt; 3 x institutional upper limit normal unless liver involved tumor , case aspartate transaminase must &lt; 5 x institutional upper limit normal Patients must histologically prove adenocarcinoma esophagus gastric cardia progression despite prior chemotherapy Patients must disease radiologically measurable bidimensionally Patients must interval 4 week prior chemotherapy , immunotherapy , radiation therapy Patients active uncontrolled infection Patients psychiatric disorder would interfere consent followup Patients history myocardial infarction within previous six month congestive heart failure require therapy Patients history prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree least five year Pregnant lactating woman . Men woman reproductive potential may participate unless agree use effective contraceptive method Presence clinically apparent central nervous system metastases carcinomatous meningitis Patients uncontrolled diabetes mellitus Patients severe concurrent disease , judgment investigator , would make patient inappropriate entry study Prior therapy deoxyribonucleic acid ( DNA ) topoisomerase inhibitor Patients know Gilbert 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>